APA
Ressing M. E., van Leeuwen D., Verreck F. A. W., Keating S., Gomez R., Franken K. L. M. C., Ottenhoff T. H. M., Spriggs M., Schumacher T. N., Hutt-Fletcher L. M., Rowe M. & Wiertz E. J. H. J. (20050127). Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. : Journal of virology.
Chicago
Ressing Maaike E, van Leeuwen Daphne, Verreck Frank A W, Keating Sinéad, Gomez Raquel, Franken Kees L M C, Ottenhoff Tom H M, Spriggs Melanie, Schumacher Ton N, Hutt-Fletcher Lindsey M, Rowe Martin and Wiertz Emmanuel J H J. 20050127. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. : Journal of virology.
Harvard
Ressing M. E., van Leeuwen D., Verreck F. A. W., Keating S., Gomez R., Franken K. L. M. C., Ottenhoff T. H. M., Spriggs M., Schumacher T. N., Hutt-Fletcher L. M., Rowe M. and Wiertz E. J. H. J. (20050127). Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. : Journal of virology.
MLA
Ressing Maaike E, van Leeuwen Daphne, Verreck Frank A W, Keating Sinéad, Gomez Raquel, Franken Kees L M C, Ottenhoff Tom H M, Spriggs Melanie, Schumacher Ton N, Hutt-Fletcher Lindsey M, Rowe Martin and Wiertz Emmanuel J H J. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. : Journal of virology. 20050127.